Associated Papers
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Data-Driven Ensemble Docking to Map Molecular Interactions of Steroid Analogs with Hepatic Organic Anion Transporting Polypeptides.
Tuerkova A et al.
Journal of Chemical Information and Modeling, 2021
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).
Lee HH et al.
British Journal of Clinical Pharmacology, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups.
Namgoong S et al.
Environmental Toxicology and Pharmacology, 2015
Hormone metabolism pathway genes and mammographic density change after quitting estrogen and progestin combined hormone therapy in the California Teachers Study.
Lee E et al.
Breast Cancer Research : Bcr, 2014
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.
Niemi M et al.
Pharmacological Reviews, 2011
Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.
König J
Handbook of Experimental Pharmacology, 2011
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Fahrmayr C et al.
Drug Metabolism Reviews, 2010
Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy.
Furihata T et al.
The Pharmacogenomics Journal, 2009
Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations.
Mwinyi J et al.
European Journal of Clinical Pharmacology, 2008
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Seithel A et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations.
Jada SR et al.
European Journal of Clinical Pharmacology, 2007
Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA et al.
Clinical Pharmacology and Therapeutics, 2006
Pharmacogenomics of human OATP transporters.
König J et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2006
Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).
Iwai M et al.
Pharmacogenetics, 2004
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Nishizato Y et al.
Clinical Pharmacology and Therapeutics, 2003
An evolutionarily ancient Oatp: insights into conserved functional domains of these proteins.
Cai SY et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology, 2002
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans.
Tirona RG et al.
The Journal of Biological Chemistry, 2001
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0